This added to the $20M funding round announced last week.
The company intends to use the funds for development of additional connected medicines for the treatment of chronic respiratory disease, such as injectables for severe asthma, and expansion into new therapeutic areas, which may include immunology, diabetes, migraine and other diseases with high unmet medical need.
Led by David Van Sickle, co-founder and CEO, Propeller Health provides a platform that enables medical technology and pharmaceutical companies to conceptualize, develop and commercialize digital medicines.
The company also offers distribution at scale through its network of leading payers, pharmacies and PBMs such as Express Scripts.
Propeller recently announced a strategic partnership with Aptar Pharma to collaborate on the development of digital medicines for multiple therapeutic areas and diseases. In addition, the company is working with industry experts and regulators to advance clinical research, evidence and the design and validation of novel endpoints.
Propeller’s platform is backed by 8 FDA 510(k) clearances and CE marking, and the company continues to expand its global operations, now spanning 16 countries.